(Q45399145)

14 December 2017

title

Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response (English)

1 reference

14 December 2017

1 reference

1 reference

1 reference

5

1 reference

14 December 2017

Daniel Yee-Tak Fong

2

0 references

Ching-Lung Lai

object named as

Ching-Lung Lai

6

0 references

author name string

Man-Fung Yuen

1

1 reference

14 December 2017

Danny Ka-Ho Wong

3

1 reference

14 December 2017

John Chi-Hang Yuen

4

1 reference

14 December 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

14 December 2017

1 reference

14 December 2017

volume

46

1 reference

14 December 2017

issue

6

1 reference

14 December 2017

page(s)

1695-1703

1 reference

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B

14 December 2017

cites work

1 reference

Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy

21 January 2018

1 reference

21 January 2018

1 reference

7 January 2021

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

1 reference

7 January 2021

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

1 reference

7 January 2021

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

7 January 2021

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

1 reference

7 January 2021

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

1 reference

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

7 January 2021

Comparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B: results of 24 weeks of therapy

1 reference

7 January 2021

Evaluation of the MagNA Pure LC used with the TRUGENE HBV Genotyping Kit

1 reference

7 January 2021

Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus.

1 reference

7 January 2021

Index for rating diagnostic tests

1 reference

7 January 2021

Identification of HBV DNA sequences that are predictive of response to lamivudine therapy

1 reference

7 January 2021

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.

1 reference

7 January 2021

Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B

1 reference

7 January 2021

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

1 reference

7 January 2021

Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine

1 reference

7 January 2021

Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy

1 reference

7 January 2021

Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group

1 reference

7 January 2021

Core promoter/pre-core mutations are associated with lamivudine-induced HBeAg loss in chronic hepatitis B with genotype C.

1 reference

7 January 2021

Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21939

1 reference

14 December 2017

1 reference